Found: 3
Select item for more details and to access through your institution.
Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-018-35367-7
- By:
- Publication type:
- Article
Health benefits and risks during 10 years after Roux-en-Y gastric bypass.
- Published in:
- Surgical Endoscopy & Other Interventional Techniques, 2020, v. 34, n. 12, p. 5368, doi. 10.1007/s00464-019-07328-2
- By:
- Publication type:
- Article
Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-54117-6
- By:
- Publication type:
- Article